Did you know ? If you order before Friday 14h we deliver 90PCT of the the time next Tuesday, GENTAUR another in time delivery

Optineurin (E3-14.7K-interacting protein) (FIP-2) (Huntingtin yeast partner L) (Huntingtin-interacting protein 7) (HIP-7) (Huntingtin-interacting protein L) (NEMO-related protein) (Optic neuropathy-inducing protein) (Transcription factor IIIA-interacting protein) (TFIIIA-IntP)

 OPTN_HUMAN              Reviewed;         577 AA.
Q96CV9; B3KP00; D3DRS4; D3DRS8; Q5T672; Q5T673; Q5T674; Q5T675;
Q7LDL9; Q8N562; Q9UET9; Q9UEV4; Q9Y218;
29-MAR-2005, integrated into UniProtKB/Swiss-Prot.
11-JAN-2011, sequence version 2.
27-SEP-2017, entry version 138.
RecName: Full=Optineurin;
AltName: Full=E3-14.7K-interacting protein;
AltName: Full=FIP-2;
AltName: Full=Huntingtin yeast partner L;
AltName: Full=Huntingtin-interacting protein 7;
Short=HIP-7;
AltName: Full=Huntingtin-interacting protein L;
AltName: Full=NEMO-related protein;
AltName: Full=Optic neuropathy-inducing protein;
AltName: Full=Transcription factor IIIA-interacting protein;
Short=TFIIIA-IntP;
Name=OPTN; Synonyms=FIP2, GLC1E, HIP7, HYPL, NRP;
Homo sapiens (Human).
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
Catarrhini; Hominidae; Homo.
NCBI_TaxID=9606;
[1]
NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORMS 1 AND 3), VARIANTS
SER-201; HIS-213; ARG-216; GLU-322 AND PRO-357, SUBCELLULAR LOCATION,
TISSUE SPECIFICITY, INDUCTION, AND INTERACTION WITH ADENOVIRUS E3.
TISSUE=Cervix carcinoma;
PubMed=9488477; DOI=10.1128/MCB.18.3.1601;
Li Y., Kang J., Horwitz M.S.;
"Interaction of an adenovirus E3 14.7-kilodalton protein with a novel
tumor necrosis factor alpha-inducible cellular protein containing
leucine zipper domains.";
Mol. Cell. Biol. 18:1601-1610(1998).
[2]
NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, SUBCELLULAR
LOCATION, TISSUE SPECIFICITY, VARIANTS GLC1E LYS-50 AND GLN-545, AND
VARIANTS LYS-98; SER-201; HIS-213; ARG-216; GLU-322 AND PRO-357.
TISSUE=Trabecular meshwork;
PubMed=11834836; DOI=10.1126/science.1066901;
Rezaie T., Child A., Hitchings R., Brice G., Miller L.,
Coca-Prados M., Heon E., Krupin T., Ritch R., Kreutzer D., Crick R.P.,
Sarfarazi M.;
"Adult-onset primary open-angle glaucoma caused by mutations in
optineurin.";
Science 295:1077-1079(2002).
[3]
NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS SER-201; HIS-213;
ARG-216; GLU-322 AND PRO-357.
Li D., Roberts R.;
"Human FIP-2: genomic structure and mutational analysis in ARVD
patients.";
Submitted (JUN-2000) to the EMBL/GenBank/DDBJ databases.
[4]
NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT
GLU-322.
TISSUE=Brain;
PubMed=14702039; DOI=10.1038/ng1285;
Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
"Complete sequencing and characterization of 21,243 full-length human
cDNAs.";
Nat. Genet. 36:40-45(2004).
[5]
NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT GLU-322.
PubMed=15164054; DOI=10.1038/nature02462;
Deloukas P., Earthrowl M.E., Grafham D.V., Rubenfield M., French L.,
Steward C.A., Sims S.K., Jones M.C., Searle S., Scott C., Howe K.,
Hunt S.E., Andrews T.D., Gilbert J.G.R., Swarbreck D., Ashurst J.L.,
Taylor A., Battles J., Bird C.P., Ainscough R., Almeida J.P.,
Ashwell R.I.S., Ambrose K.D., Babbage A.K., Bagguley C.L., Bailey J.,
Banerjee R., Bates K., Beasley H., Bray-Allen S., Brown A.J.,
Brown J.Y., Burford D.C., Burrill W., Burton J., Cahill P., Camire D.,
Carter N.P., Chapman J.C., Clark S.Y., Clarke G., Clee C.M., Clegg S.,
Corby N., Coulson A., Dhami P., Dutta I., Dunn M., Faulkner L.,
Frankish A., Frankland J.A., Garner P., Garnett J., Gribble S.,
Griffiths C., Grocock R., Gustafson E., Hammond S., Harley J.L.,
Hart E., Heath P.D., Ho T.P., Hopkins B., Horne J., Howden P.J.,
Huckle E., Hynds C., Johnson C., Johnson D., Kana A., Kay M.,
Kimberley A.M., Kershaw J.K., Kokkinaki M., Laird G.K., Lawlor S.,
Lee H.M., Leongamornlert D.A., Laird G., Lloyd C., Lloyd D.M.,
Loveland J., Lovell J., McLaren S., McLay K.E., McMurray A.,
Mashreghi-Mohammadi M., Matthews L., Milne S., Nickerson T.,
Nguyen M., Overton-Larty E., Palmer S.A., Pearce A.V., Peck A.I.,
Pelan S., Phillimore B., Porter K., Rice C.M., Rogosin A., Ross M.T.,
Sarafidou T., Sehra H.K., Shownkeen R., Skuce C.D., Smith M.,
Standring L., Sycamore N., Tester J., Thorpe A., Torcasso W.,
Tracey A., Tromans A., Tsolas J., Wall M., Walsh J., Wang H.,
Weinstock K., West A.P., Willey D.L., Whitehead S.L., Wilming L.,
Wray P.W., Young L., Chen Y., Lovering R.C., Moschonas N.K.,
Siebert R., Fechtel K., Bentley D., Durbin R.M., Hubbard T.,
Doucette-Stamm L., Beck S., Smith D.R., Rogers J.;
"The DNA sequence and comparative analysis of human chromosome 10.";
Nature 429:375-381(2004).
[6]
NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
Venter J.C.;
Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
[7]
NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2), AND VARIANT
GLU-322.
TISSUE=Cervix, and Skin;
PubMed=15489334; DOI=10.1101/gr.2596504;
The MGC Project Team;
"The status, quality, and expansion of the NIH full-length cDNA
project: the Mammalian Gene Collection (MGC).";
Genome Res. 14:2121-2127(2004).
[8]
NUCLEOTIDE SEQUENCE [MRNA] OF 412-555, AND INTERACTION WITH HD.
TISSUE=Testis;
PubMed=9700202; DOI=10.1093/hmg/7.9.1463;
Faber P.W., Barnes G.T., Srinidhi J., Chen J., Gusella J.F.,
MacDonald M.E.;
"Huntingtin interacts with a family of WW domain proteins.";
Hum. Mol. Genet. 7:1463-1474(1998).
[9]
INTERACTION WITH HD AND RAB8.
PubMed=11137014; DOI=10.1016/S0960-9822(00)00864-2;
Hattula K., Peraenen J.;
"FIP-2, a coiled-coil protein, links Huntingtin to Rab8 and modulates
cellular morphogenesis.";
Curr. Biol. 10:1603-1606(2000).
[10]
SUBCELLULAR LOCATION, INDUCTION, AND PHOSPHORYLATION.
PubMed=10807909; DOI=10.1074/jbc.M001500200;
Schwamborn K., Weil R., Courtois G., Whiteside S.T., Israeel A.;
"Phorbol esters and cytokines regulate the expression of the NEMO-
related protein, a molecule involved in a NF-kappa B-independent
pathway.";
J. Biol. Chem. 275:22780-22789(2000).
[11]
INTERACTION WITH GTF3A.
PubMed=10756201; DOI=10.1093/nar/28.9.1986;
Moreland R.J., Dresser M.E., Rodgers J.S., Roe B.A., Conaway J.W.,
Conaway R.C., Hanas J.S.;
"Identification of a transcription factor IIIA-interacting protein.";
Nucleic Acids Res. 28:1986-1993(2000).
[12]
INDUCTION.
PubMed=12379221; DOI=10.1016/S0006-291X(02)02395-1;
Vittitow J., Borras T.;
"Expression of optineurin, a glaucoma-linked gene, is influenced by
elevated intraocular pressure.";
Biochem. Biophys. Res. Commun. 298:67-74(2002).
[13]
INDUCTION.
PubMed=12646749; DOI=10.1159/000069133;
Kamphuis W., Schneemann A.;
"Optineurin gene expression level in human trabecular meshwork does
not change in response to pressure elevation.";
Ophthalmic Res. 35:93-96(2003).
[14]
FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH MYO6 AND RAB8.
PubMed=15837803; DOI=10.1083/jcb.200501162;
Sahlender D.A., Roberts R.C., Arden S.D., Spudich G., Taylor M.J.,
Luzio J.P., Kendrick-Jones J., Buss F.;
"Optineurin links myosin VI to the Golgi complex and is involved in
Golgi organization and exocytosis.";
J. Cell Biol. 169:285-295(2005).
[15]
IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
TISSUE=Cervix carcinoma;
PubMed=16964243; DOI=10.1038/nbt1240;
Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.;
"A probability-based approach for high-throughput protein
phosphorylation analysis and site localization.";
Nat. Biotechnol. 24:1285-1292(2006).
[16]
IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
TISSUE=Cervix carcinoma;
PubMed=18669648; DOI=10.1073/pnas.0805139105;
Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
Elledge S.J., Gygi S.P.;
"A quantitative atlas of mitotic phosphorylation.";
Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
[17]
FUNCTION, SUBCELLULAR LOCATION, INTERACTION WITH TFRC AND RAB8A,
MUTAGENESIS OF GLU-50 AND ASP-474, AND CHARACTERIZATION OF VARIANT
GLC1E LYS-50.
PubMed=20085643; DOI=10.1186/1471-2121-11-4;
Nagabhushana A., Chalasani M.L., Jain N., Radha V., Rangaraj N.,
Balasubramanian D., Swarup G.;
"Regulation of endocytic trafficking of transferrin receptor by
optineurin and its impairment by a glaucoma-associated mutant.";
BMC Cell Biol. 11:4-4(2010).
[18]
FUNCTION, SUBCELLULAR LOCATION, INDUCTION, INTERACTION WITH TBK1 AND
TRAF3, UBIQUITIN-BINDING MOTIF, AND MUTAGENESIS OF ASP-474.
PubMed=20174559; DOI=10.1371/journal.ppat.1000778;
Mankouri J., Fragkoudis R., Richards K.H., Wetherill L.F., Harris M.,
Kohl A., Elliott R.M., Macdonald A.;
"Optineurin negatively regulates the induction of IFNbeta in response
to RNA virus infection.";
PLoS Pathog. 6:E1000778-E1000778(2010).
[19]
IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
TISSUE=Cervix carcinoma;
PubMed=20068231; DOI=10.1126/scisignal.2000475;
Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
Mann M.;
"Quantitative phosphoproteomics reveals widespread full
phosphorylation site occupancy during mitosis.";
Sci. Signal. 3:RA3-RA3(2010).
[20]
IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
PubMed=21406692; DOI=10.1126/scisignal.2001570;
Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
Blagoev B.;
"System-wide temporal characterization of the proteome and
phosphoproteome of human embryonic stem cell differentiation.";
Sci. Signal. 4:RS3-RS3(2011).
[21]
FUNCTION, SUBCELLULAR LOCATION, INTERACTION WITH TBC1D17, INTERACTION
WITH RAB8A, AND CHARACTERIZATION OF VARIANT GLC1E LYS-50.
PubMed=22854040; DOI=10.1242/jcs.102327;
Vaibhava V., Nagabhushana A., Chalasani M.L., Sudhakar C., Kumari A.,
Swarup G.;
"Optineurin mediates a negative regulation of Rab8 by the GTPase-
activating protein TBC1D17.";
J. Cell Sci. 125:5026-5039(2012).
[22]
IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
PubMed=22814378; DOI=10.1073/pnas.1210303109;
Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E.,
Timmerman E., Prieto J., Arnesen T., Sherman F., Gevaert K.,
Aldabe R.;
"N-terminal acetylome analyses and functional insights of the N-
terminal acetyltransferase NatB.";
Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
[23]
LIR MOTIF.
PubMed=23908376; DOI=10.1242/jcs.126128;
Birgisdottir A.B., Lamark T., Johansen T.;
"The LIR motif - crucial for selective autophagy.";
J. Cell Sci. 126:3237-3247(2013).
[24]
PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-177 AND SER-526, AND
IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
TISSUE=Cervix carcinoma, and Erythroleukemia;
PubMed=23186163; DOI=10.1021/pr300630k;
Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
Mohammed S.;
"Toward a comprehensive characterization of a human cancer cell
phosphoproteome.";
J. Proteome Res. 12:260-271(2013).
[25]
PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-177; SER-198 AND
SER-342, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
ANALYSIS].
TISSUE=Liver;
PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
Wang L., Ye M., Zou H.;
"An enzyme assisted RP-RPLC approach for in-depth analysis of human
liver phosphoproteome.";
J. Proteomics 96:253-262(2014).
[26]
X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 170-181, STRUCTURE BY NMR OF
169-185, INTERACTION WITH MAP1LC3B, AND MUTAGENESIS OF MUTAGENESIS OF
PHE-178.
PubMed=23805866; DOI=10.1042/BJ20121907;
Rogov V.V., Suzuki H., Fiskin E., Wild P., Kniss A., Rozenknop A.,
Kato R., Kawasaki M., McEwan D.G., Lohr F., Guntert P., Dikic I.,
Wakatsuki S., Dotsch V.;
"Structural basis for phosphorylation-triggered autophagic clearance
of Salmonella.";
Biochem. J. 454:459-466(2013).
[27]
VARIANT LYS-98.
PubMed=14627677; DOI=10.1136/jmg.40.11.842;
Melki R., Belmouden A., Akhayat O., Brezin A., Garchon H.-J.;
"The M98K variant of the OPTINEURIN (OPTN) gene modifies initial
intraocular pressure in patients with primary open angle glaucoma.";
J. Med. Genet. 40:842-844(2003).
[28]
VARIANTS GLC1E ASP-103 AND ARG-486.
PubMed=12939304; DOI=10.1167/iovs.02-0693;
Leung Y.F., Fan B.J., Lam D.S.C., Lee W.S., Tam P.O.S., Chua J.K.H.,
Tham C.C.Y., Lai J.S.M., Fan D.S.P., Pang C.P.;
"Different optineurin mutation pattern in primary open-angle
glaucoma.";
Invest. Ophthalmol. Vis. Sci. 44:3880-3884(2003).
[29]
VARIANT GLC1E GLN-545.
PubMed=14597044; DOI=10.1016/S0002-9394(03)00577-4;
Alward W.L.M., Kwon Y.H., Kawase K., Craig J.E., Hayreh S.S.,
Johnson A.T., Khanna C.L., Yamamoto T., Mackey D.A., Roos B.R.,
Affatigato L.M., Sheffield V.C., Stone E.M.;
"Evaluation of optineurin sequence variations in 1,048 patients with
open-angle glaucoma.";
Am. J. Ophthalmol. 136:904-910(2003).
[30]
CHARACTERIZATION OF VARIANT LYS-98, AND INTERACTION WITH RAB12.
PubMed=23357852; DOI=10.4161/auto.23458;
Sirohi K., Chalasani M.L., Sudhakar C., Kumari A., Radha V.,
Swarup G.;
"M98K-OPTN induces transferrin receptor degradation and RAB12-mediated
autophagic death in retinal ganglion cells.";
Autophagy 9:510-527(2013).
[31]
SUBCELLULAR LOCATION, CHARACTERIZATION OF VARIANT GLC1E LYS-50, AND
MUTAGENESIS OF GLU-50 AND ASP-474.
PubMed=24752605; DOI=10.1371/journal.pone.0095758;
Chalasani M.L., Kumari A., Radha V., Swarup G.;
"E50K-OPTN-induced retinal cell death involves the Rab GTPase-
activating protein, TBC1D17 mediated block in autophagy.";
PLoS ONE 9:E95758-E95758(2014).
[32]
SELF-ASSOCIATION, SUBCELLULAR LOCATION, INTERACTION WITH TBK1, AND
CHARACTERIZATION OF VARIANT GLC1E LYS-50.
PubMed=23669351; DOI=10.1093/hmg/ddt210;
Minegishi Y., Iejima D., Kobayashi H., Chi Z.L., Kawase K.,
Yamamoto T., Seki T., Yuasa S., Fukuda K., Iwata T.;
"Enhanced optineurin E50K-TBK1 interaction evokes protein insolubility
and initiates familial primary open-angle glaucoma.";
Hum. Mol. Genet. 22:3559-3567(2013).
[33]
VARIANT LYS-98.
PubMed=15498064; DOI=10.1111/j.1442-9071.2004.00886.x;
Baird P.N., Richardson A.J., Craig J.E., Mackey D.A., Rochtchina E.,
Mitchell P.;
"Analysis of optineurin (OPTN) gene mutations in subjects with and
without glaucoma: the blue mountains eye study.";
Clin. Exp. Ophthalmol. 32:518-522(2004).
[34]
VARIANT GLC1E ARG-486.
PubMed=15326130; DOI=10.1167/iovs.04-0107;
Willoughby C.E., Chan L.L.Y., Herd S., Billingsley G., Noordeh N.,
Levin A.V., Buys Y., Trope G., Sarfarazi M., Heon E.;
"Defining the pathogenicity of optineurin in juvenile open-angle
glaucoma.";
Invest. Ophthalmol. Vis. Sci. 45:3122-3130(2004).
[35]
VARIANTS GLC1E ASP-26 AND GLN-545, AND VARIANT LYS-98.
PubMed=15557444; DOI=10.1167/iovs.03-1403;
Funayama T., Ishikawa K., Ohtake Y., Tanino T., Kurosaka D.,
Kimura I., Suzuki K., Ideta H., Nakamoto K., Yasuda N., Fujimaki T.,
Murakami A., Asaoka R., Hotta Y., Tanihara H., Kanamoto T.,
Mishima H., Fukuchi T., Abe H., Iwata T., Shimada N., Kudoh J.,
Shimizu N., Mashima Y.;
"Variants in optineurin gene and their association with tumor necrosis
factor-alpha polymorphisms in Japanese patients with glaucoma.";
Invest. Ophthalmol. Vis. Sci. 45:4359-4367(2004).
[36]
VARIANT GLC1E ASP-26.
PubMed=15226658; DOI=10.1097/00061198-200408000-00007;
Fuse N., Takahashi K., Akiyama H., Nakazawa T., Seimiya M.,
Kuwahara S., Tamai M.;
"Molecular genetic analysis of optineurin gene for primary open-angle
and normal tension glaucoma in the Japanese population.";
J. Glaucoma 13:299-303(2004).
[37]
VARIANT NPG ASP-26.
PubMed=15370540; DOI=10.1080/13816810490514298;
Umeda T., Matsuo T., Nagayama M., Tamura N., Tanabe Y., Ohtsuki H.;
"Clinical relevance of optineurin sequence alterations in Japanese
glaucoma patients.";
Ophthalmic Genet. 25:91-99(2004).
[38]
CHARACTERIZATION OF VARIANT GLC1E LYS-50.
PubMed=17389490; DOI=10.1167/iovs.06-0834;
Chalasani M.L., Radha V., Gupta V., Agarwal N., Balasubramanian D.,
Swarup G.;
"A glaucoma-associated mutant of optineurin selectively induces death
of retinal ganglion cells which is inhibited by antioxidants.";
Invest. Ophthalmol. Vis. Sci. 48:1607-1614(2007).
[39]
VARIANT ALS12 GLY-478, AND SUBCELLULAR LOCATION.
PubMed=20428114; DOI=10.1038/nature08971;
Maruyama H., Morino H., Ito H., Izumi Y., Kato H., Watanabe Y.,
Kinoshita Y., Kamada M., Nodera H., Suzuki H., Komure O., Matsuura S.,
Kobatake K., Morimoto N., Abe K., Suzuki N., Aoki M., Kawata A.,
Hirai T., Kato T., Ogasawara K., Hirano A., Takumi T., Kusaka H.,
Hagiwara K., Kaji R., Kawakami H.;
"Mutations of optineurin in amyotrophic lateral sclerosis.";
Nature 465:223-226(2010).
[40]
FUNCTION, SUBCELLULAR LOCATION, INTERACTION WITH MAP1LC3A; MAP1LC3B;
GABARAP; GABARAPL1 AND GABARAPL2, PHOSPHORYLATION AT SER-177 BY TBK1,
UBIQUITIN-BINDING, AND MUTAGENESIS OF PHE-178 AND 474-ASP-PHE-475.
PubMed=21617041; DOI=10.1126/science.1205405;
Wild P., Farhan H., McEwan D.G., Wagner S., Rogov V.V., Brady N.R.,
Richter B., Korac J., Waidmann O., Choudhary C., Dotsch V., Bumann D.,
Dikic I.;
"Phosphorylation of the autophagy receptor optineurin restricts
Salmonella growth.";
Science 333:228-233(2011).
[41]
VARIANT ALS12 PHE-295, CHARACTERIZATION VARIANT ALS12 PHE-295,
FUNCTION, AND SUBCELLULAR LOCATION.
PubMed=27534431; DOI=10.1080/21678421.2016.1218517;
Fifita J.A., Williams K.L., Sundaramoorthy V., Mccann E.P.,
Nicholson G.A., Atkin J.D., Blair I.P.;
"A novel amyotrophic lateral sclerosis mutation in OPTN induces ER
stress and Golgi fragmentation in vitro.";
Amyotroph. Lateral Scler. Frontotemporal Degener. 18:126-133(2017).
-!- FUNCTION: Plays an important role in the maintenance of the Golgi
complex, in membrane trafficking, in exocytosis, through its
interaction with myosin VI and Rab8 (PubMed:27534431). Links
myosin VI to the Golgi complex and plays an important role in
Golgi ribbon formation (PubMed:27534431). Negatively regulates the
induction of IFNB in response to RNA virus infection. Plays a
neuroprotective role in the eye and optic nerve. Probably part of
the TNF-alpha signaling pathway that can shift the equilibrium
toward induction of cell death. May act by regulating membrane
trafficking and cellular morphogenesis via a complex that contains
Rab8 and hungtingtin (HD). Mediates the interaction of Rab8 with
the probable GTPase-activating protein TBC1D17 during Rab8-
mediated endocytic trafficking, such as of transferrin receptor
(TFRC/TfR); regulates Rab8 recruitnment to tubules emanating from
the endocytic recycling compartment. Autophagy receptor that
interacts directly with both the cargo to become degraded and an
autophagy modifier of the MAP1 LC3 family; targets ubiquitin-
coated bacteria (xenophagy), such as cytoplasmic Salmonella
enterica, and appears to function in the same pathway as SQSTM1
and CALCOCO2/NDP52. May constitute a cellular target for
adenovirus E3 14.7, an inhibitor of TNF-alpha functions, thereby
affecting cell death. {ECO:0000269|PubMed:11834836,
ECO:0000269|PubMed:15837803, ECO:0000269|PubMed:20085643,
ECO:0000269|PubMed:20174559, ECO:0000269|PubMed:21617041,
ECO:0000269|PubMed:22854040, ECO:0000269|PubMed:27534431}.
-!- SUBUNIT: Interacts with HD, Rab8 (RAB8A and/or RAB8B) (active GTP-
bound form), GTF3A, TRAF3, TBK1, MYO6 and TFRC. Binds to linear
ubiquitin chains. Interacts with LC3 family members MAP1LC3A,
MAP1LC3B, GABARAP, GABARAPL1 and GABARAPL2; OPTN phosphorylation
increases the association (at least with MAP1LC3B). Self-
associates. Interacts with RAB12; the interaction may be indirect.
Interacts with E3 14.7 kDa protein of group C human adenovirus.
{ECO:0000269|PubMed:10756201, ECO:0000269|PubMed:11137014,
ECO:0000269|PubMed:15837803, ECO:0000269|PubMed:20085643,
ECO:0000269|PubMed:20174559, ECO:0000269|PubMed:21617041,
ECO:0000269|PubMed:22854040, ECO:0000269|PubMed:23357852,
ECO:0000269|PubMed:23669351, ECO:0000269|PubMed:23805866,
ECO:0000269|PubMed:9488477, ECO:0000269|PubMed:9700202}.
-!- INTERACTION:
Self; NbExp=12; IntAct=EBI-748974, EBI-748974;
Q99IB8:- (xeno); NbExp=3; IntAct=EBI-748974, EBI-6858501;
Q12904-2:AIMP1; NbExp=4; IntAct=EBI-748974, EBI-12412735;
Q13023:AKAP6; NbExp=2; IntAct=EBI-748974, EBI-1056102;
Q9UJX2:CDC23; NbExp=8; IntAct=EBI-748974, EBI-396137;
Q15038:DAZAP2; NbExp=5; IntAct=EBI-748974, EBI-724310;
Q03001:DST; NbExp=2; IntAct=EBI-748974, EBI-310758;
O75923:DYSF; NbExp=3; IntAct=EBI-748974, EBI-2799016;
Q8IYU2:HACE1; NbExp=15; IntAct=EBI-748974, EBI-308277;
P42858:HTT; NbExp=9; IntAct=EBI-748974, EBI-466029;
P40325:HUA1 (xeno); NbExp=3; IntAct=EBI-748974, EBI-23614;
Q99732:LITAF; NbExp=3; IntAct=EBI-9091423, EBI-725647;
Q00013:MPP1; NbExp=2; IntAct=EBI-748974, EBI-711788;
P54845-1:NRL; NbExp=6; IntAct=EBI-748974, EBI-9819090;
P40302:PRE5 (xeno); NbExp=3; IntAct=EBI-9091423, EBI-13955;
O75360:PROP1; NbExp=4; IntAct=EBI-748974, EBI-9027467;
P61026:RAB10; NbExp=3; IntAct=EBI-748974, EBI-726075;
P61006:RAB8A; NbExp=4; IntAct=EBI-748974, EBI-722293;
P61007:RAB8A (xeno); NbExp=2; IntAct=EBI-748974, EBI-7473289;
Q9NTZ6:RBM12; NbExp=5; IntAct=EBI-748974, EBI-310707;
P40454:RRD1 (xeno); NbExp=3; IntAct=EBI-9091423, EBI-25278;
Q14BN4:SLMAP; NbExp=2; IntAct=EBI-748974, EBI-1043216;
Q9UNH7:SNX6; NbExp=2; IntAct=EBI-748974, EBI-949294;
Q13501:SQSTM1; NbExp=7; IntAct=EBI-748974, EBI-307104;
Q8TC07:TBC1D15; NbExp=5; IntAct=EBI-748974, EBI-1048247;
Q9HA65:TBC1D17; NbExp=7; IntAct=EBI-748974, EBI-714625;
Q9UHD2:TBK1; NbExp=12; IntAct=EBI-748974, EBI-356402;
Q15025:TNIP1; NbExp=12; IntAct=EBI-748974, EBI-357849;
Q8WZ42:TTN; NbExp=2; IntAct=EBI-748974, EBI-681210;
P04275:VWF; NbExp=2; IntAct=EBI-748974, EBI-981819;
Q9Y3C0:WASHC3; NbExp=12; IntAct=EBI-748974, EBI-712969;
P01123:YPT1 (xeno); NbExp=3; IntAct=EBI-9091423, EBI-29496;
Q8IUH5:ZDHHC17; NbExp=2; IntAct=EBI-9091423, EBI-524753;
Q86UD4:ZNF329; NbExp=3; IntAct=EBI-748974, EBI-7233259;
Q8TD17:ZNF398; NbExp=3; IntAct=EBI-748974, EBI-8643207;
Q9BUY5:ZNF426; NbExp=3; IntAct=EBI-748974, EBI-743265;
Q9BS34:ZNF670; NbExp=5; IntAct=EBI-748974, EBI-745276;
-!- SUBCELLULAR LOCATION: Cytoplasm, perinuclear region. Golgi
apparatus {ECO:0000269|PubMed:27534431}. Golgi apparatus, trans-
Golgi network. Cytoplasmic vesicle, autophagosome. Cytoplasmic
vesicle. Recycling endosome. Note=Found in the perinuclear region
and associates with the Golgi apparatus (PubMed:27534431).
Colocalizes with MYO6 and RAB8 at the Golgi complex and in
vesicular structures close to the plasma membrane. Localizes to
LC3-positive cytoplasmic vesicles upon induction of autophagy.
{ECO:0000269|PubMed:27534431}.
-!- ALTERNATIVE PRODUCTS:
Event=Alternative splicing; Named isoforms=3;
Name=1;
IsoId=Q96CV9-1; Sequence=Displayed;
Name=2;
IsoId=Q96CV9-2; Sequence=VSP_013262;
Note=No experimental confirmation available.;
Name=3;
IsoId=Q96CV9-3; Sequence=VSP_013261;
-!- TISSUE SPECIFICITY: Present in aqueous humor of the eye (at
protein level). Highly expressed in trabecular meshwork. Expressed
nonpigmented ciliary epithelium, retina, brain, adrenal cortex,
fetus, lymphocyte, fibroblast, skeletal muscle, heart, liver,
brain and placenta. {ECO:0000269|PubMed:11834836,
ECO:0000269|PubMed:9488477}.
-!- INDUCTION: Upon TNF and interferon treatments. Up-regulated in
direct response to viral infection. {ECO:0000269|PubMed:10807909,
ECO:0000269|PubMed:12379221, ECO:0000269|PubMed:12646749,
ECO:0000269|PubMed:20174559, ECO:0000269|PubMed:9488477}.
-!- DOMAIN: Ubiquitin-binding motif (UBAN) is essential for its
inhibitory function, subcellular localization and interaction with
TBK1.
-!- DOMAIN: The LIR (LC3-interacting region) motif mediates the
interaction with ATG8 family proteins.
{ECO:0000269|PubMed:23908376}.
-!- PTM: Phosphorylated by TBK1, leading to restrict bacterial
proliferation in case of infection. Phosphorylation is induced by
phorbol esters and decreases its half-time.
{ECO:0000269|PubMed:10807909, ECO:0000269|PubMed:21617041}.
-!- DISEASE: Glaucoma 1, open angle, E (GLC1E) [MIM:137760]: A form of
primary open angle glaucoma (POAG). POAG is characterized by a
specific pattern of optic nerve and visual field defects. The
angle of the anterior chamber of the eye is open, and usually the
intraocular pressure is increased. However, glaucoma can occur at
any intraocular pressure. The disease is generally asymptomatic
until the late stages, by which time significant and irreversible
optic nerve damage has already taken place.
{ECO:0000269|PubMed:11834836, ECO:0000269|PubMed:12939304,
ECO:0000269|PubMed:14597044, ECO:0000269|PubMed:15226658,
ECO:0000269|PubMed:15326130, ECO:0000269|PubMed:15557444,
ECO:0000269|PubMed:17389490, ECO:0000269|PubMed:20085643,
ECO:0000269|PubMed:22854040, ECO:0000269|PubMed:23669351,
ECO:0000269|PubMed:24752605}. Note=The disease is caused by
mutations affecting the gene represented in this entry.
-!- DISEASE: Glaucoma, normal pressure (NPG) [MIM:606657]: A primary
glaucoma characterized by intraocular pression consistently within
the statistically normal population range.
{ECO:0000269|PubMed:15370540}. Note=Disease susceptibility is
associated with variations affecting the gene represented in this
entry.
-!- DISEASE: Amyotrophic lateral sclerosis 12 (ALS12) [MIM:613435]: A
neurodegenerative disorder affecting upper motor neurons in the
brain and lower motor neurons in the brain stem and spinal cord,
resulting in fatal paralysis. Sensory abnormalities are absent.
The pathologic hallmarks of the disease include pallor of the
corticospinal tract due to loss of motor neurons, presence of
ubiquitin-positive inclusions within surviving motor neurons, and
deposition of pathologic aggregates. The etiology of amyotrophic
lateral sclerosis is likely to be multifactorial, involving both
genetic and environmental factors. The disease is inherited in 5-
10% of the cases. {ECO:0000269|PubMed:20428114,
ECO:0000269|PubMed:27534431}. Note=The disease is caused by
mutations affecting the gene represented in this entry.
-!- CAUTION: According to some authors (PubMed:12379221) its
expression is regulated by intraocular pressure, suggesting a
protective role in case of high pressure, while according to other
authors (PubMed:12646749), it is not up-regulated in response to
pressure elevation. {ECO:0000305|PubMed:12379221,
ECO:0000305|PubMed:12646749}.
-!- CAUTION: Interaction of variant GLC1E LYS-50 with Rab8 is reported
conflictingly. Coimmunoprecipitation experiments with
overexpressed proteins suggested an increased interaction
(PubMed:20085643) while yeast-two-hybrid (PubMed:22854040) and
protein complentation assays with an equivalent mouse Optn
construct (AC Q8K3K8) failed to show an interaction.
{ECO:0000305|PubMed:20085643, ECO:0000305|PubMed:22854040}.
-!- SEQUENCE CAUTION:
Sequence=CAI16552.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305};
-----------------------------------------------------------------------
Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
Distributed under the Creative Commons Attribution-NoDerivs License
-----------------------------------------------------------------------
EMBL; AF061034; AAC16046.1; -; mRNA.
EMBL; AF061034; AAC16047.1; -; mRNA.
EMBL; AF420371; AAL76327.1; -; mRNA.
EMBL; AF420372; AAL76328.1; -; mRNA.
EMBL; AF420373; AAL76329.1; -; mRNA.
EMBL; AF283527; AAG00497.1; -; Genomic_DNA.
EMBL; AF283520; AAG00497.1; JOINED; Genomic_DNA.
EMBL; AF283521; AAG00497.1; JOINED; Genomic_DNA.
EMBL; AF283522; AAG00497.1; JOINED; Genomic_DNA.
EMBL; AF283523; AAG00497.1; JOINED; Genomic_DNA.
EMBL; AF283524; AAG00497.1; JOINED; Genomic_DNA.
EMBL; AF283525; AAG00497.1; JOINED; Genomic_DNA.
EMBL; AF283526; AAG00497.1; JOINED; Genomic_DNA.
EMBL; AK055403; BAG51512.1; -; mRNA.
EMBL; AL355355; CAI16549.1; -; Genomic_DNA.
EMBL; AL355355; CAI16550.1; -; Genomic_DNA.
EMBL; AL355355; CAI16551.1; -; Genomic_DNA.
EMBL; AL355355; CAI16552.1; ALT_SEQ; Genomic_DNA.
EMBL; CH471072; EAW86301.1; -; Genomic_DNA.
EMBL; CH471072; EAW86302.1; -; Genomic_DNA.
EMBL; CH471072; EAW86303.1; -; Genomic_DNA.
EMBL; CH471072; EAW86304.1; -; Genomic_DNA.
EMBL; CH471072; EAW86306.1; -; Genomic_DNA.
EMBL; CH471072; EAW86308.1; -; Genomic_DNA.
EMBL; CH471072; EAW86309.1; -; Genomic_DNA.
EMBL; BC013876; AAH13876.1; -; mRNA.
EMBL; BC032762; AAH32762.1; -; mRNA.
EMBL; AF049614; AAC26850.1; -; mRNA.
CCDS; CCDS7094.1; -. [Q96CV9-1]
RefSeq; NP_001008212.1; NM_001008211.1.
RefSeq; NP_001008213.1; NM_001008212.1.
RefSeq; NP_001008214.1; NM_001008213.1.
RefSeq; NP_068815.2; NM_021980.4.
UniGene; Hs.332706; -.
PDB; 2LO4; NMR; -; A=550-577.
PDB; 2LUE; NMR; -; B=169-185.
PDB; 3VTV; X-ray; 1.70 A; A=170-181.
PDB; 3VTW; X-ray; 2.52 A; A/B/C=170-181.
PDB; 5AAZ; NMR; -; A=548-577.
PDB; 5B83; X-ray; 2.69 A; B/C/E/F=416-510.
PDB; 5EOA; X-ray; 2.50 A; A/B=26-103.
PDB; 5EOF; X-ray; 2.05 A; A/B=26-103.
PDBsum; 2LO4; -.
PDBsum; 2LUE; -.
PDBsum; 3VTV; -.
PDBsum; 3VTW; -.
PDBsum; 5AAZ; -.
PDBsum; 5B83; -.
PDBsum; 5EOA; -.
PDBsum; 5EOF; -.
ProteinModelPortal; Q96CV9; -.
SMR; Q96CV9; -.
BioGrid; 115436; 78.
CORUM; Q96CV9; -.
DIP; DIP-42001N; -.
IntAct; Q96CV9; 95.
MINT; MINT-155870; -.
STRING; 9606.ENSP00000263036; -.
iPTMnet; Q96CV9; -.
PhosphoSitePlus; Q96CV9; -.
BioMuta; OPTN; -.
DMDM; 317373403; -.
EPD; Q96CV9; -.
MaxQB; Q96CV9; -.
PaxDb; Q96CV9; -.
PeptideAtlas; Q96CV9; -.
PRIDE; Q96CV9; -.
DNASU; 10133; -.
Ensembl; ENST00000263036; ENSP00000263036; ENSG00000123240.
Ensembl; ENST00000378747; ENSP00000368021; ENSG00000123240.
Ensembl; ENST00000378748; ENSP00000368022; ENSG00000123240.
Ensembl; ENST00000378752; ENSP00000368027; ENSG00000123240.
Ensembl; ENST00000378757; ENSP00000368032; ENSG00000123240.
Ensembl; ENST00000378764; ENSP00000368040; ENSG00000123240.
GeneID; 10133; -.
KEGG; hsa:10133; -.
UCSC; uc001ilv.2; human. [Q96CV9-1]
CTD; 10133; -.
DisGeNET; 10133; -.
EuPathDB; HostDB:ENSG00000123240.16; -.
GeneCards; OPTN; -.
GeneReviews; OPTN; -.
HGNC; HGNC:17142; OPTN.
HPA; CAB019303; -.
HPA; HPA003279; -.
HPA; HPA003360; -.
MalaCards; OPTN; -.
MIM; 137760; phenotype.
MIM; 602432; gene.
MIM; 606657; phenotype.
MIM; 613435; phenotype.
neXtProt; NX_Q96CV9; -.
Orphanet; 803; Amyotrophic lateral sclerosis.
Orphanet; 353225; Primary adult open-angle glaucoma.
PharmGKB; PA31948; -.
eggNOG; ENOG410IE97; Eukaryota.
eggNOG; ENOG410Z0DF; LUCA.
HOVERGEN; HBG106481; -.
InParanoid; Q96CV9; -.
KO; K19946; -.
OrthoDB; EOG091G0576; -.
PhylomeDB; Q96CV9; -.
TreeFam; TF326608; -.
Reactome; R-HSA-2565942; Regulation of PLK1 Activity at G2/M Transition.
Reactome; R-HSA-8854214; TBC/RABGAPs.
SIGNOR; Q96CV9; -.
ChiTaRS; OPTN; human.
GeneWiki; Optineurin; -.
GenomeRNAi; 10133; -.
PRO; PR:Q96CV9; -.
Proteomes; UP000005640; Chromosome 10.
Bgee; ENSG00000123240; -.
ExpressionAtlas; Q96CV9; baseline and differential.
Genevisible; Q96CV9; HS.
GO; GO:0005776; C:autophagosome; IEA:UniProtKB-SubCell.
GO; GO:0005737; C:cytoplasm; TAS:ProtInc.
GO; GO:0031410; C:cytoplasmic vesicle; IBA:GO_Central.
GO; GO:0005829; C:cytosol; IDA:HPA.
GO; GO:0005794; C:Golgi apparatus; IDA:UniProtKB.
GO; GO:0000139; C:Golgi membrane; TAS:Reactome.
GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
GO; GO:0005634; C:nucleus; IBA:GO_Central.
GO; GO:0048471; C:perinuclear region of cytoplasm; IEA:UniProtKB-SubCell.
GO; GO:0055038; C:recycling endosome membrane; TAS:Reactome.
GO; GO:0005802; C:trans-Golgi network; IDA:UniProtKB.
GO; GO:0042802; F:identical protein binding; IPI:IntAct.
GO; GO:0070530; F:K63-linked polyubiquitin modification-dependent protein binding; IBA:GO_Central.
GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
GO; GO:0031593; F:polyubiquitin modification-dependent protein binding; IDA:UniProtKB.
GO; GO:0030674; F:protein binding, bridging; IPI:ParkinsonsUK-UCL.
GO; GO:0008022; F:protein C-terminus binding; IPI:UniProtKB.
GO; GO:0017137; F:Rab GTPase binding; IPI:UniProtKB.
GO; GO:0043130; F:ubiquitin binding; IEA:InterPro.
GO; GO:0006914; P:autophagy; IEA:UniProtKB-KW.
GO; GO:0008219; P:cell death; TAS:ProtInc.
GO; GO:0034620; P:cellular response to unfolded protein; IMP:UniProtKB.
GO; GO:0050829; P:defense response to Gram-negative bacterium; IMP:UniProtKB.
GO; GO:0000086; P:G2/M transition of mitotic cell cycle; TAS:Reactome.
GO; GO:0007030; P:Golgi organization; IMP:UniProtKB.
GO; GO:0090161; P:Golgi ribbon formation; IDA:UniProtKB.
GO; GO:0043001; P:Golgi to plasma membrane protein transport; IMP:UniProtKB.
GO; GO:0061024; P:membrane organization; TAS:Reactome.
GO; GO:0043124; P:negative regulation of I-kappaB kinase/NF-kappaB signaling; IEA:Ensembl.
GO; GO:0001920; P:negative regulation of receptor recycling; IMP:UniProtKB.
GO; GO:0061734; P:parkin-mediated stimulation of mitophagy in response to mitochondrial depolarization; IMP:ParkinsonsUK-UCL.
GO; GO:0010508; P:positive regulation of autophagy; IDA:GO_Central.
GO; GO:1904417; P:positive regulation of xenophagy; IMP:ParkinsonsUK-UCL.
GO; GO:0000042; P:protein targeting to Golgi; IMP:UniProtKB.
GO; GO:0043122; P:regulation of I-kappaB kinase/NF-kappaB signaling; IBA:GO_Central.
GO; GO:0007165; P:signal transduction; TAS:ProtInc.
InterPro; IPR032419; CC2-LZ_dom.
InterPro; IPR021063; NEMO_N.
InterPro; IPR034735; NEMO_ZF.
InterPro; IPR032939; Optineurin.
PANTHER; PTHR31553:SF6; PTHR31553:SF6; 1.
Pfam; PF16516; CC2-LZ; 1.
Pfam; PF11577; NEMO; 1.
PROSITE; PS51801; ZF_CCHC_NOA; 1.
1: Evidence at protein level;
3D-structure; Alternative splicing; Amyotrophic lateral sclerosis;
Autophagy; Coiled coil; Complete proteome; Cytoplasm;
Cytoplasmic vesicle; Disease mutation; Endosome; Glaucoma;
Golgi apparatus; Metal-binding; Neurodegeneration; Phosphoprotein;
Polymorphism; Reference proteome; Zinc; Zinc-finger.
CHAIN 1 577 Optineurin.
/FTId=PRO_0000058066.
ZN_FING 547 577 CCHC NOA-type. {ECO:0000255|PROSITE-
ProRule:PRU01142}.
REGION 58 209 Interaction with Rab8.
REGION 411 577 Interaction with HD.
REGION 412 520 Interaction with MYO6.
{ECO:0000269|PubMed:15837803}.
COILED 38 170 {ECO:0000255}.
COILED 239 508 {ECO:0000255}.
MOTIF 176 181 LIR.
MOTIF 474 479 UBAN.
MOD_RES 177 177 Phosphoserine; by TBK1.
{ECO:0000244|PubMed:23186163,
ECO:0000244|PubMed:24275569,
ECO:0000269|PubMed:21617041}.
MOD_RES 198 198 Phosphoserine.
{ECO:0000244|PubMed:24275569}.
MOD_RES 342 342 Phosphoserine.
{ECO:0000244|PubMed:24275569}.
MOD_RES 526 526 Phosphoserine.
{ECO:0000244|PubMed:23186163}.
VAR_SEQ 1 57 Missing (in isoform 3).
{ECO:0000303|PubMed:9488477}.
/FTId=VSP_013261.
VAR_SEQ 210 215 Missing (in isoform 2).
{ECO:0000303|PubMed:15489334}.
/FTId=VSP_013262.
VARIANT 26 26 H -> D (in GLC1E).
{ECO:0000269|PubMed:15226658,
ECO:0000269|PubMed:15370540,
ECO:0000269|PubMed:15557444}.
/FTId=VAR_021537.
VARIANT 50 50 E -> K (in GLC1E; selectively promotes
cell death of retinal ganglion cells
probably by inducing TBC1D17-mediated
inhibition of autophagy; altered
interaction with RAB8A; no effect on
interaction with TBC1D17; increases
interaction with TFRC and impairs its
endocytic recycling; increases
interactions with TBK1; decreases self-
association; disturbs transition from the
ER to Golgi; dbSNP:rs28939688).
{ECO:0000269|PubMed:11834836,
ECO:0000269|PubMed:17389490,
ECO:0000269|PubMed:20085643,
ECO:0000269|PubMed:22854040,
ECO:0000269|PubMed:23669351,
ECO:0000269|PubMed:24752605}.
/FTId=VAR_021538.
VARIANT 98 98 M -> K (polymorphism; may modify
intraocular pressure and increase risk of
GLC1E and NPG; induces TFRC degradation
leading to autophagic death in retinal
ganglion cells; dbSNP:rs11258194).
{ECO:0000269|PubMed:11834836,
ECO:0000269|PubMed:14627677,
ECO:0000269|PubMed:15498064,
ECO:0000269|PubMed:15557444,
ECO:0000269|PubMed:23357852}.
/FTId=VAR_021539.
VARIANT 103 103 E -> D (in GLC1E).
{ECO:0000269|PubMed:12939304}.
/FTId=VAR_021540.
VARIANT 201 201 P -> S. {ECO:0000269|PubMed:11834836,
ECO:0000269|PubMed:9488477,
ECO:0000269|Ref.3}.
/FTId=VAR_021541.
VARIANT 213 213 K -> H (requires 2 nucleotide
substitutions).
{ECO:0000269|PubMed:11834836,
ECO:0000269|PubMed:9488477,
ECO:0000269|Ref.3}.
/FTId=VAR_021542.
VARIANT 216 216 S -> R. {ECO:0000269|PubMed:11834836,
ECO:0000269|PubMed:9488477,
ECO:0000269|Ref.3}.
/FTId=VAR_021543.
VARIANT 295 295 V -> F (in ALS12; no effect on Golgi
subcellular location; no effect on
protein expression level; increased Golgi
fragmentation; decreased Golgi ribbon
formation; increased susceptibility to
endoplasmic reticulum (ER) stress).
{ECO:0000269|PubMed:27534431}.
/FTId=VAR_078108.
VARIANT 308 308 S -> P (in dbSNP:rs7068431).
/FTId=VAR_030769.
VARIANT 322 322 K -> E (in dbSNP:rs523747).
{ECO:0000269|PubMed:11834836,
ECO:0000269|PubMed:14702039,
ECO:0000269|PubMed:15164054,
ECO:0000269|PubMed:15489334,
ECO:0000269|PubMed:9488477,
ECO:0000269|Ref.3}.
/FTId=VAR_021544.
VARIANT 357 357 T -> P. {ECO:0000269|PubMed:11834836,
ECO:0000269|PubMed:9488477,
ECO:0000269|Ref.3}.
/FTId=VAR_021545.
VARIANT 478 478 E -> G (in ALS12).
{ECO:0000269|PubMed:20428114}.
/FTId=VAR_063597.
VARIANT 486 486 H -> R (in GLC1E; juvenile onset).
{ECO:0000269|PubMed:12939304,
ECO:0000269|PubMed:15326130}.
/FTId=VAR_021546.
VARIANT 545 545 R -> Q (in GLC1E; unknown pathological
significance; dbSNP:rs28939689).
{ECO:0000269|PubMed:11834836,
ECO:0000269|PubMed:14597044,
ECO:0000269|PubMed:15557444}.
/FTId=VAR_021547.
MUTAGEN 50 50 E->K: Reduces cell death, decreased
interaction with TFRC; when associated
with N-474. {ECO:0000269|PubMed:20085643,
ECO:0000269|PubMed:24752605}.
MUTAGEN 178 178 F->A: Abolishes interaction with MAP1LC3A
and GABARAPL1, no effect on binding to
linear ubiquitin.
{ECO:0000269|PubMed:21617041,
ECO:0000269|PubMed:23805866}.
MUTAGEN 178 178 F->W: Increases interaction with
MAP1LC3B. {ECO:0000269|PubMed:21617041,
ECO:0000269|PubMed:23805866}.
MUTAGEN 474 475 DF->NA: Abolishes colocalization with
cytosolic Salmonella.
{ECO:0000269|PubMed:21617041}.
MUTAGEN 474 474 D->N: Reduces cell death, decreased
interaction with TFRC; when associated
with K-50. {ECO:0000269|PubMed:20085643,
ECO:0000269|PubMed:20174559,
ECO:0000269|PubMed:24752605}.
MUTAGEN 474 474 D->N: Significant reduction in ubiquitin
binding and interaction with TBK1.
Inhibits localization to recycling
endosomes and disrupts interaction with
TFRC. Loss of ability to inhibit the
activation of the IFNB promoter in
response to TLR3 or RIG-I signaling.
{ECO:0000269|PubMed:20085643,
ECO:0000269|PubMed:20174559,
ECO:0000269|PubMed:24752605}.
CONFLICT 436 436 A -> V (in Ref. 8; AAC26850).
{ECO:0000305}.
TURN 30 33 {ECO:0000244|PDB:5EOF}.
HELIX 37 98 {ECO:0000244|PDB:5EOF}.
STRAND 178 180 {ECO:0000244|PDB:2LUE}.
HELIX 447 497 {ECO:0000244|PDB:5B83}.
TURN 556 560 {ECO:0000244|PDB:2LO4}.
STRAND 561 564 {ECO:0000244|PDB:5AAZ}.
HELIX 566 574 {ECO:0000244|PDB:2LO4}.
SEQUENCE 577 AA; 65921 MW; DB0F841E3315AAE1 CRC64;
MSHQPLSCLT EKEDSPSEST GNGPPHLAHP NLDTFTPEEL LQQMKELLTE NHQLKEAMKL
NNQAMKGRFE ELSAWTEKQK EERQFFEIQS KEAKERLMAL SHENEKLKEE LGKLKGKSER
SSEDPTDDSR LPRAEAEQEK DQLRTQVVRL QAEKADLLGI VSELQLKLNS SGSSEDSFVE
IRMAEGEAEG SVKEIKHSPG PTRTVSTGTA LSKYRSRSAD GAKNYFEHEE LTVSQLLLCL
REGNQKVERL EVALKEAKER VSDFEKKTSN RSEIETQTEG STEKENDEEK GPETVGSEVE
ALNLQVTSLF KELQEAHTKL SKAELMKKRL QEKCQALERK NSAIPSELNE KQELVYTNKK
LELQVESMLS EIKMEQAKTE DEKSKLTVLQ MTHNKLLQEH NNALKTIEEL TRKESEKVDR
AVLKELSEKL ELAEKALASK QLQMDEMKQT IAKQEEDLET MTILRAQMEV YCSDFHAERA
AREKIHEEKE QLALQLAVLL KENDAFEDGG RQSLMEMQSR HGARTSDSDQ QAYLVQRGAE
DRDWRQQRNI PIHSCPKCGE VLPDIDTLQI HVMDCII


Related products :

Catalog number Product name Quantity
EIAAB28928 E3-14.7K-interacting protein,FIP2,FIP-2,GLC1E,HIP7,HIP-7,Homo sapiens,Human,Huntingtin yeast partner L,Huntingtin-interacting protein 7,Huntingtin-interacting protein L,HYPL,NEMO-related protein,NRP,O
EIAAB46979 DHHC-17,HIP14,HIP-14,HIP3,HIP-3,Homo sapiens,HSPC294,Human,Huntingtin yeast partner H,Huntingtin-interacting protein 14,Huntingtin-interacting protein 3,Huntingtin-interacting protein H,HYPH,KIAA0946,
EIAAB37961 HIF1,HIF-1,HIP-1,Histone-lysine N-methyltransferase SETD2,Homo sapiens,hSET2,HSPC069,Human,Huntingtin yeast partner B,Huntingtin-interacting protein 1,Huntingtin-interacting protein B,HYPB,KIAA1732,KM
EIAAB46969 DHHC-13,HIP14L,HIP14-related protein,HIP3RP,Homo sapiens,Human,Huntingtin-interacting protein 14-related protein,Huntingtin-interacting protein HIP3RP,Palmitoyltransferase ZDHHC13,Putative MAPK-activa
EIAAB32202 Huntingtin yeast partner C,Huntingtin-interacting protein C,Hypc,Mouse,Mus musculus,Pre-mRNA-processing factor 40 homolog B,Prpf40b
EIAAB32201 Homo sapiens,Human,Huntingtin yeast partner C,Huntingtin-interacting protein C,HYPC,Pre-mRNA-processing factor 40 homolog B,PRPF40B
EIAAB32199 Fas ligand-associated factor 1,FBP11,FLAF1,FNBP3,Formin-binding protein 11,Formin-binding protein 3,HIP10,HIP-10,Homo sapiens,HSPC225,Human,Huntingtin yeast partner A,Huntingtin-interacting protein 10
20-372-60246 huntingtin interacting protein 2 (HIP2) - Mouse monoclonal anti-human HIP2 antibody; EC 6.3.2.19; Ubiquitin-protein ligase; Ubiquitin carrier protein; E2(25K); Huntingtin-interacting protein 2; HIP-2 0.1 mg
EIAAB34857 BAP1,DING,E3 ubiquitin-protein ligase RING2,HIP2-interacting protein 3,HIPI3,Homo sapiens,Human,Huntingtin-interacting protein 2-interacting protein 3,Protein DinG,RING finger protein 1B,RING finger p
EIAAB27017 45 kDa NF-AT-interacting protein,45 kDa NFAT-interacting protein,Homo sapiens,Human,NFATC2-interacting protein,NFATC2IP,NIP45,Nuclear factor of activated T-cells, cytoplasmic 2-interacting protein
EIAAB27018 45 kDa NF-AT-interacting protein,45 kDa NFAT-interacting protein,Mouse,Mus musculus,NFATC2-interacting protein,Nfatc2ip,Nip45,Nuclear factor of activated T-cells, cytoplasmic 2-interacting protein
CSB-EL010366MO Mouse Huntingtin-interacting protein 1-related protein(HIP1R) ELISA kit 96T
CSB-EL010366HU Human Huntingtin-interacting protein 1-related protein(HIP1R) ELISA kit 96T
HIP1R_HUMAN Human ELISA Kit FOR Huntingtin-interacting protein 1-related protein 96T
18-003-42501 Ubiquitin ligase protein RING2 - EC 6.3.2.-; RING finger protein 2; RING finger protein 1B; RING1b; RING finger protein BAP-1; DinG protein; Huntingtin-interacting protein 2-interacting protein 3; HIP 0.05 mg Aff Pur
18-003-42502 Ubiquitin ligase protein RING2 - EC 6.3.2.-; RING finger protein 2; RING finger protein 1B; RING1b; RING finger protein BAP-1; DinG protein; Huntingtin-interacting protein 2-interacting protein 3; HIP 0.1 mg Protein A
CSB-EL010366HU Human Huntingtin-interacting protein 1-related protein(HIP1R) ELISA kit SpeciesHuman 96T
CSB-EL010366MO Mouse Huntingtin-interacting protein 1-related protein(HIP1R) ELISA kit SpeciesMouse 96T
HIP1R_MOUSE ELISA Kit FOR Huntingtin-interacting protein 1-related protein; organism: Mouse; gene name: Hip1r 96T
EIAAB39347 Mouse,Mus musculus,Spata24,Spermatogenesis-associated protein 24,TATA-binding protein-like factor-interacting protein,Testis protein T6441 homolog,Tipt,Tipt2,TLF-interacting protein,TRF2-interacting p
EIAAB44012 Homo sapiens,Human,OIP1,OIP-1,Opa-interacting protein 1,Thyroid receptor-interacting protein 6,TR-interacting protein 6,TRIP6,TRIP-6,ZRP-1,Zyxin-related protein 1
HIPK2 HIP1R Gene huntingtin interacting protein 1 related
201-20-2534 HIP1R{huntingtin interacting protein 1 related}rabbit.pAb 0.2ml
EIAAB37933 Huntingtin-interacting protein-like protein,Mouse,Mus musculus,SEC14 domain and spectrin repeat-containing protein 1,Sestd1
EIAAB46968 DHHC-13,Hip14l,HIP14-related protein,Huntingtin-interacting protein 14-related protein,Mouse,Mus musculus,Palmitoyltransferase ZDHHC13,Zdhhc13,Zinc finger DHHC domain-containing protein 13


 

GENTAUR Belgium BVBA BE0473327336
Voortstraat 49, 1910 Kampenhout BELGIUM
Tel 0032 16 58 90 45

Fax 0032 16 50 90 45
info@gentaur.com | Gentaur





GENTAUR Ltd.
Howard Frank Turnberry House
1404-1410 High Road
Whetstone London N20 9BH
Tel 020 3393 8531 Fax 020 8445 9411
uk@gentaur.com | Gentaur

 

 




GENTAUR France SARL
9, rue Lagrange, 75005 Paris
Tel 01 43 25 01 50

Fax 01 43 25 01 60
RCS Paris B 484 237 888

SIRET 48423788800017

BNP PARIBAS PARIS PL MAUBERT BIC BNPAFRPPPRG

france@gentaur.com | Gentaur

GENTAUR GmbH
Marienbongard 20
52062 Aachen Deutschland
Support Karolina Elandt
Tel: 0035929830070
Fax: (+49) 241 56 00 47 88

Logistic :0241 40 08 90 86
Bankleitzahl 39050000
IBAN lautet DE8839050000107569353
Handelsregister Aachen HR B 16058
Umsatzsteuer-Identifikationsnummer *** DE 815175831
Steuernummer 201/5961/3925
de@gentaur.com | Gentaur

GENTAUR U.S.A
Genprice Inc, Logistics
547, Yurok Circle
San Jose, CA 95123
CA 95123
Tel (408) 780-0908,
Fax (408) 780-0908,
sales@genprice.com

Genprice Inc, Invoices and accounting
6017 Snell Ave, Ste 357
San Jose, CA 95123




GENTAUR Nederland BV
NL850396268B01 KVK nummer 52327027
Kuiper 1
5521 DG Eersel Nederland
Tel:  0208-080893  Fax: 0497-517897
nl@gentaur.com | Gentaur
IBAN: NL04 RABO 0156 9854 62   SWIFT RABONL2U






GENTAUR Spain
tel:0911876558
spain@gentaur.com | Gentaur






ГЕНТАУЪР БЪЛГАРИЯ
ID # 201 358 931 /BULSTAT
София 1000, ул. "Граф Игнатиев" 53 вх. В, ет. 2
Tel 0035924682280 Fax 0035924808322
e-mail: Sofia@gentaur.com | Gentaur
IBAN: BG11FINV91501014771636
BIC: FINVBGSF

GENTAUR Poland Sp. z o.o.


ul. Grunwaldzka 88/A m.2
81-771 Sopot, Poland
TEL Gdansk 058 710 33 44 FAX  058 710 33 48              

poland@gentaur.com | Gentaur

Other countries

Österreich +43720880899

Canada Montreal +15149077481

Ceská republika Praha +420246019719

Danmark +4569918806

Finland Helsset +358942419041

Magyarország Budapest +3619980547

Ireland Dublin+35316526556

Luxembourg+35220880274

Norge Oslo+4721031366

Sverige Stockholm+46852503438

Schweiz Züri+41435006251

US New York+17185132983

GENTAUR Italy
SRL IVA IT03841300167
Piazza Giacomo Matteotti, 6
24122 Bergamo Tel 02 36 00 65 93
Fax 02 36 00 65 94
italia@gentaur.com | Gentaur